Boston Scientific CorporationBSXNYSE
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +19.34% | +22.44% | +20.93% | +22.84% | +20.34% |
| Gross Profit Growth | +22.20% | +15.53% | +23.74% | +32.46% | +33.76% |
| EBITDA Growth | +8.40% | +21.02% | +23.68% | +68.35% | -3.02% |
| Operating Income Growth | +20.79% | +5.56% | +39.13% | +9.64% | +55.79% |
| Net Income Growth | -6.94% | +12.30% | +36.44% | +144.75% | +60.98% |
| EPS Growth | -7.63% | +11.60% | +35.36% | +145.12% | +60.13% |
| EPS Diluted Growth | -7.91% | +11.28% | +35.11% | +142.79% | +58.58% |
| Weighted Average Shares Growth | +0.56% | +0.61% | +0.60% | +0.54% | +0.61% |
| Weighted Average Shares Diluted Growth | +0.84% | +0.90% | +0.77% | +0.61% | +0.54% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +43.55% | +52.14% | +229.88% | +58.18% | +0.00% |
| Free Cash Flow Growth | +41.87% | +68.55% | +0.00% | +66.57% | +0.00% |
| Receivables Growth | +19.04% | +14.81% | +16.88% | +17.29% | +0.00% |
| Inventory Growth | +14.52% | +13.12% | +11.95% | +9.70% | +0.00% |
| Asset Growth | +11.85% | +12.12% | +9.47% | +11.99% | +0.00% |
| Book Value per Share Growth | +9.04% | +12.23% | +10.81% | +9.46% | +0.00% |
| Debt Growth | +21.07% | +17.44% | +6.43% | +9.98% | +0.00% |
| R&D Expense Growth | +14.33% | +26.72% | +21.04% | +37.34% | +26.29% |
| SG&A Expenses Growth | +25.76% | +16.90% | +17.08% | +18.67% | +11.46% |